Search

Displaying results 4271 - 4280 of 8577 in total
  1. Drug

    Streptococcus pneumoniae type 12f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10331
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  2. Drug

    Streptococcus pneumoniae type 19f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10336
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  3. Drug

    Streptococcus pneumoniae type 33f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10341
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  4. Drug

    Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells

    go.drugbank.com/drugs/DB28348
    Approved

    [L54146] Zemcelpro was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation following myeloablative conditioning

  5. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials. … Unlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD.

  6. Drug

    Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)

    go.drugbank.com/drugs/DB15863
    Experimental

    As of June, 2020, safety and Immunogenicity trials are currently underway for this vaccine (NCT04470609 & NCT04412538). … This vaccine specifically was developed in collaboration with the Chinese Academy of Medical Sciences, West China Second University Hospital, and Yunan Center for Disease Control and Prevention.

  7. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.

  8. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. … NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body.

  9. Drug

    Evofosfamide

    go.drugbank.com/drugs/DB06091
    Investigational

    TH-302 has been shown, in preclinical studies, to be both efficacious and well tolerated. … TH-302 is a nitroimidazole-linked prodrug of a brominated derivative of an isophosphoramide mustard previously used in cancer drugs such as ifosfamide, cyclophosphamide, and glufosfamide.

    Synonyms: (1-methyl-2-nitro-1H-imidazol-5-YL)methyl N,N'-bis(2-bromoethyl)diamidophosphate, (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate
  10. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication an...